ACTG230 RECOMBINANT HIV 1 ENVELOPE ANTIGEN IN CHILDREN OF HIV INFECTED MOTHERS

ACTG230 重组 HIV 1 包膜抗原在 HIV 感染母亲的孩子中

• 批准号: 6116859
• 负责人: Stuart E Starr
• 金额: $ 2.47万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116859
• 关键词: AIDS education /prevention; AIDS vaccines; HIV envelope protein; clinical research; clinical trial phase I; drug screening /evaluation; enzyme linked immunosorbent assay; helper T lymphocyte; human immunodeficiency virus 1; human subject; human therapy evaluation; infant human (0-1 year); lymphocyte proliferation; pediatric AIDS; recombinant proteins; vertical transmission; virus antigen

ACTG 230 is a phase I study to evaluate recombinant HIV-1 envelope vaccines in children born to HIV infected mothers. Enrollment has been completed. All vaccines tested were well tolerated. Preliminary analysis indicates that newborns produced ELISA antibodies and developed HIV specific lymphocyte proliferation responses.

ACTG 230 是一项评估重组 HIV-1 包膜的 I 期研究 感染艾滋病毒的母亲所生的孩子接种疫苗。报名已 完全的。所有测试的疫苗都具有良好的耐受性。初步分析 表明新生儿产生 ELISA 抗体并感染 HIV 特异性淋巴细胞增殖反应。